Modern Pediatrics. Ukraine. (2026).1(153): 96-102. doi: 10.15574/SP.2026.1(153).96102
Kurylo H. V.^1,2
1Danylo Halytsky Lviv National Medical University, Ukraine
²Lviv Territorial Medical Association "Multidisciplinary Clinical Hospital of Intensive Care and Emergency Medical Care", Ukraine

For citation: Kurylo HV. (2026). Progressive familial intrahepatic cholestasis in children: clinical features, diagnosis, and management. Modern Pediatrics. Ukraine. 1(153): 96-102. doi: 10.15574/SP.2026.1(153).96102.
Article received: Dec 04, 2025. Accepted for publication: Feb 08, 2026.

Progressive Familial Intrahepatic Cholestasis (PFIC) is a rare genetically determined liver disorder characterized by impaired bile secretion at the hepatocellular level and progressive cholestasis. The disease typically manifests in early childhood and leads to pruritus, jaundice, malabsorption, and growth retardation. Without timely treatment, it progresses to biliary cirrhosis, liver failure, and the need for liver transplantation.
Aim – to evaluate the clinical, biochemical, and psychophysical manifestations of PFIC in children, as well as the effectiveness of different treatment approaches.
Materials and methods. Seven children with PFIC (2019-2024) were observed and underwent comprehensive clinical, biochemical, and instrumental evaluation. Physical development was assessed using body mass index (BMI) and developmental quotient (DQ), while psycho-emotional status was evaluated using a modified Hamilton Anxiety Rating Scale. Pruritus intensity was assessed using the Visual Analog Scale (VAS). Treatment included conservative therapy, ileal bile acid transporter inhibitors (IBAT inhibitors), and surgical biliary diversion.
Results. All patients with PFIC1 and PFIC2 presented with jaundice and pruritus (VAS 6-10), whereas patients with PFIC3 had jaundice in 50% of cases and milder pruritus (VAS 5-7). Biochemical parameters indicated pronounced cholestasis. BMI and DQ demonstrated impaired physical and psychomotor development, particularly in PFIC2 cases. Conservative therapy improved biochemical parameters in 3 of 5 patients. IBAT inhibitors resulted in significant reduction of pruritus and improvement in quality of life in 2 children. Surgical intervention with subsequent liver transplantation restored liver function and resolved pruritus in 2 patients.
Conclusions. Genetic testing is the gold standard for the diagnosis of PFIC. Management of this condition should be performed in specialized multidisciplinary centers using pathogenetically targeted approaches, including IBAT inhibitors, ursodeoxycholic acid, surgical interventions, and liver transplantation in severe cases. Early diagnosis and comprehensive therapy can slow disease progression, improve quality of life, and delay the need for transplantation.
The study was conducted in accordance with the principles of the Declaration of Helsinki. The research protocol was approved by the Local Ethics Committee of the institution. Informed parental consent was obtained for participation in the study.
The author declares no conflict of interest.
Keywords: Progressive Familial Intrahepatic Cholestasis, children, ileal bile acid transporter inhibitors, liver transplantation.
REFERENCES:

1. Bakulin IG, Bereznitskaya MM, Avalueva EB. (2025). Progressive familial intrahepatic cholestasis: literature review and clinical case. Therapy. 11(10): 114-124. https://doi.org/10.18565/therapy.2025.10.114-124

2. Bedoyan SM, Lovell OT, Horslen SP, Squires JE. (2022). Odevixibat: a promising new treatment for progressive familial intrahepatic cholestasis. Expert Opin Pharmacother. 23(16): 1771-1779. https://doi.org/10.1080/14656566.2022.2140040; PMid:36278881 PMCid:PMC10074157

3. Chen YT, Su YC, Or YE, Cheng CF, Kung JT. (2023). CD8 + T cell memory is sustained in mice by hepatic stellate cells. Hepatology. 77(5): 1486-1498. https://doi.org/10.1002/hep.32788; PMid:36106384 PMCid:PMC10113002

4. De Groot ADE, Chiadò C, Kosterink JGW, Lexmond WS, Mian P, Verkade HJ. (2026). Ileal bile acid transporter inhibitors in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis: A systematic review into dose-response. Br J Clin Pharmacol. 92(1): 119-135. Epub 2025 Sep 30. https://doi.org/10.1002/bcp.70277; PMid:41025998 PMCid:PMC12746362

5. Hassan S, Hertel P. (2022). Overview of Progressive Familial Intrahepatic Cholestasis. Clin Liver Dis. 26(3): 371-390. https://doi.org/10.1016/j.cld.2022.03.003; PMid:35868680

6. Hof WFJ, de Boer JF, Verkade HJ. (2024). Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials. Expert Opin Emerg Drugs. 29(3): 305-320. https://doi.org/10.1080/14728214.2024.2336986; PMid:38571480

7. Jones Hughes T, Campbell J, Crathorne L. (2021). Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review. Orphanet J Rare Dis. 16(1): 255. https://doi.org/10.1186/s13023-021-01884-4; PMid:34082807 PMCid:PMC8173883

8. Miethke AG, Moukarzel A, Porta G, Covarrubias Esquer J, Czubkowski P, Ordonez F et al. (2024). Maralixibat in progressive familial intrahepatic cholestasis (MARCH PFIC). Lancet Gastroenterol Hepatol. 9(7): 620631. https://doi.org/10.1016/S2468-1253(24)00080-3; PMid:38723644

9. Pinon M, Kamath BM. (2024). What's new in pediatric genetic cholestatic liver disease: advances in etiology, diagnostics, and therapeutic approaches. Curr Opin Pediatr. 36(5): 524-536. https://doi.org/10.1097/MOP.0000000000001380; PMid:38957097

10. Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P et al. (2022). Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomized, placebo controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 7(9): 830-842. https://doi.org/10.1016/S2468-1253(22)00093-0; PMCid:PMC7614852